Tat-Gap 19 (trifluoroacetate salt)

Formulation: A solid

Formal Name: L-tyrosylglycyl-L-arginyl-L-lysyl-L-lysyl-L-arginyl-L-arginyl-L-glutaminyl-L-arginyl-L-arginyl-L-arginyl-L-lysyl-L-glutaminyl-L-isoleucyl-L-α-glutamyl-L-isoleucyl-L-lysyl-L-lysyl-L-phenylalanyl-L-lysine, trifluoroacetate salt

Purity: ≥95%

Formula Markup: C119H212N46O26 • XCF3COOH

Formula Weight: 2703,3

Shelf life (days): 1460

Notes: Tat-Gap 19 is a peptide inhibitor of connexin43 (Cx43) hemichannels.{59785} It is composed of the HIV-1 Tat protein transduction domain linked to a nine-amino acid peptide corresponding to residues 128-136 of Cx43. Tat-Gap 19 (10 µM) inhibits glutamate-induced ATP release, a marker of Cx43 hemichannel activity, in primary rat hepatocytes.{65897} It reduces infarct volume in a mouse model of cerebral ischemia-reperfusion injury induced by middle cerebral artery occlusion (MCAO) when administered at a dose of 25 mg/kg.{59785} Intraperitoneal infusion of Tat-Gap 19 (1 mg/kg per day) reduces fibrotic lesion area and the area of hepatic stellate cells, precursors of myofibroblasts, expressing α-smooth muscle actin (α-SMA) in a mouse model of thioacetamide-induced liver injury.{65897} It increases superoxide dismutase (SOD) activity in hepatic cells isolated from the same mice.

• Artikelnummer: CAY36729-5
• Hersteller: Cayman Chemical
• Hersteller Artikelnummer: 36729-5
• Green Labware: Nein
• Verpackungseinheit: 5 mg
• Mengeneinheit: STK